We need your help to achieve the goal of growing our online, geographically searchable database of resources and support for cancer patients, their families and caregivers. Whether you're in the initial phase of shock, in the battle, or handling the aftermath of cancer, our resources take out the stress of searching multiple places and thousands of online listings.
According to results from a Phase I/IIa trial at The University of Texas MD Anderson Cancer Center, treatment with cord blood-derived chimeric antigen receptor natural killer (NK)-cell therapy targeting CD19 resulted in clinical responses in a majority of patients with relapsed or refractory non-Hodgkin's lymphoma and chronic lymphocytic leukemia, with no major toxicities observed.
Eisai Co., Ltd. announced today that it has entered into an agreement to transfer the rights to receive royalties on the sales outside of Japan for an investigational anti-cancer agent tazemetostat (generic name) to Royalty Pharma.
Recently, a drug named Pixantrone (PIX) was developed, which is far less damaging to the heart than previous, less advanced compounds. PIX is now used to treat cancers including non-Hodgkin's lymphoma and leukaemia, but a detailed knowledge of the molecular processes it uses to destroy cancer cells has been lacking so far.
Atlantic Health System is treating patients in a new Phase 2 clinical trial of CAR T-cell therapy at Morristown Medical Center. A select number of sites across the U.S. are involved in this study, which is done on an outpatient basis.
Treating non-Hodgkin's lymphoma patients with radiation therapy as an additional treatment while they wait for their CAR T cells to be manufactured may reduce the risk of CAR T therapy side effects once it is administered, according to a new study from researchers in the Abramson Cancer Center at the University of Pennsylvania.
Cheryl Krafft was diagnosed with an aggressive form of non-Hodgkin's lymphoma and was put on a very high-powered chemotherapy regimen to rid her body of the cancer. What she was not counting on was the chemotherapy causing another equally deadly problem.
Researchers have developed an experimental cancer vaccine that when injected into a single tumour can help trigger the immune system to kill the cancer cells circulating within the body. The results of the study titled, “Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination,” were published in the latest issue of the journal Nature Medicine, this week, Monday.
A new study has shown that the herbicide glyphosphate, could increase the risk of Non-Hodgkin Lymphoma by 41 percent among those who are exposed.
According to a report from the Israel Cancer Association yesterday (3rd February 2019), there has been a significant fall in the number of Israeli men getting cancers over that last decade.
Sartorius Stedim Biotech, a leading international supplier of the biopharmaceutical industry, through its China affiliate, and Beijing-based Immunochina Pharmaceuticals, announced today that both parties have entered into a collaboration.